Navigation Links
Neovasc Inc. Reports Second Quarter 2009 Financial Results
Date:8/19/2009

     - Growing Traction in Specialty Tissue Business Producing Increased
                                 Revenues -
         - Neovasc Reducer(TM) Commercialization Process on Track -

    TSX Venture Exchange: NVC

VANCOUVER, Aug. 19 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the three and six months ended June 30, 2009.

"During the second quarter we continued to make significant progress in executing on our strategic initiatives adopted late last year," said Alexei Marko, chief executive officer of Neovasc. "We are especially pleased at the growing traction we are seeing in our tissue business, where our decision to focus on our specialty products and services is beginning to bear fruit, with increases in tissue sales already evident. We were pleased in the second quarter to report significantly lower expenses compared to last year, at the same time that we were able to advance the development of our innovative Neovasc Reducer(TM) device."

Mr. Marko continued, "While holding down costs we have also been able to ramp up our business development activities, and the response to date is very encouraging. On this note, we were delighted that LeMaitre Vascular, one of our key strategic partners, cited our Peripatch product as an important contributor to their second quarter sales growth."

Financial Results

Results for the three and six months ended June 30, 2009 follow. All amounts are in Canadian dollars.

Revenues

Revenues increased 39% year-over-year from $433,061 for the quarter ended June 30, 2008 to $600,324 for the quarter ended June 30, 2009. For the six months ended June 30, 2009, revenues increased 10% to $955,808, up from $866,546 for the six months ended June 30, 2008, primarily reflecting increased revenues from consulting and contract manufacturing services in our tissue products and services business. Sales of tissue and surgical products and services for the three months ended June 30, 2009 were $596,787, compared to $387,157 in the prior year quarter, an increase of 54%. Sales of tissue products and services for the six months ended June 30, 2009 were $936,064, as compared to sales of $740,406 for the same period of 2008, representing an increase of 26%. These revenues include sales of Neovasc's Peripatch products, as well as consulting services and contract manufacturing revenues for tissue and surgical products. The company is continuing to develop additional consulting services and contract manufacturing clients. Sales of Metricath(R) catheter products for the six months ended June 30, 2009 were $19,744, an 84% decrease over sales of $126,140 in the comparable period in 2008. The termination of our direct sales force for Metricath products at the end of 2008, a strategic decision undertaken to enable the company to focus on its most promising growth opportunities, contributed to this decrease in sales.

Cost of Sales

The cost of sales for the three and six months ended June 30, 2009 were $277,265 and $427,025, respectively, as compared to $220,344 and $428,604 in the comparable periods in 2008. The overall gross margin for the first half of 2009 rose to 55%, as compared to 51% in 2008. The improvement in gross margin reflects the company's strategic shift to certain contract and specialty tissue patch products with higher margins.

Expenses

Total expenses for the three and six months ended June 30, 2009 were $1,687,389 and $3,617,883, respectively, as compared to $2,074,216 and $3,983,750 for the same periods in 2008. Total expenses declined more than 18% year-on-year for the three-month period and more than 9% for the six-month period. Sales and marketing expenses declined 79% for the three months ended June 30, 2009, from $785,491 in 2008 to $163,683 for the same period in 2009. For the six months ended June 30, 2009, sales and marketing expenses were $466,568, compared to $1,534,995 for the same period in 2008, a 70% decrease. The company terminated its direct sales force for its catheter products in the fourth quarter of 2008 and will continue to minimize sales and marketing costs while it focuses on growing its business-to-business revenue streams. General and administrative expenses for the three and six months ended June 30, 2009 were $659,004 and $1,409,833, respectively, as compared to $779,363 and $1,317,648 for the comparable periods in 2008, a decrease of 15% for the three-month period and an increase of 7% for the six-month period. Substantially all of the increase in general and administrative expenses in the six-month period reflects an increase in stock-based compensation charges. Product development and clinical trial expenses were $864,702 and $1,741,482 respectively, for the three and six months ended June 30, 2009, as compared to $414,958 and $1,036,703 for the same periods in 2008, representing increases of 108% and 68% respectively. Product development expenditures to advance the Neovasc Reducer CE mark regulatory submission and the final Metricath Gemini PMA submission contributed to the increase.

Net Losses

The consolidated net loss for the three and six months ended June 30, 2009 was $1,330,451 and $3,076,691, or $0.05 and $0.14 basic loss per share, as compared to a net loss of $1,915,673 and $3,657,248, or $0.34 and $0.66 basic loss per share for the comparable periods in 2008. The decrease in net loss year-on-year reflects the company's increased revenues and decreased losses.

Liquidity and Capital Resources

The company finances its operations and capital expenditures with cash generated from operations, lines of credit, long-term debt and equity financings. At June 30, 2009, the company had cash and cash equivalents of $1,340,471, as compared to cash and cash equivalents of $2,498,439 at December 31, 2008. In addition, at June 30, 2009, the company had restricted cash related to a security on long-term debt of $50,000 included in long-term assets. At June 30, 2009, the company had working capital of $1,168,101, as compared to working capital of $2,123,519 at December 31, 2008. The decrease in working capital during the six months ended June 30, 2009 was predominantly due to a decline in cash and an increase in accounts receivable and in accounts payable associated with the growth in operations from the expansion of our tissue business and the development of the Neovasc Reducer. Cash used in operations was $1,593,864 and $3,108,346 for the three and six months ended June 30, 2009 respectively, as compared to $1,527,982 and $3,327,793 for the same periods of 2008. The decrease in cash usage for the six months ended June 30, 2009 as compared to the same period of 2008 is primarily the result of the company's decrease in marketing expenses in 2009. The company made minimum equipment purchases in both periods and investing activities were minimal. Net cash provided from financing activities was $1,962,399 and $1,958,923 for the three and six months ended June 30, 2009, compared to cash used of $9,920 and $16,418 in the same periods in 2008. On April 23, 2009, the company completed a non-brokered private placement of 9,523,810 units at the price of $0.21 per unit for aggregate gross proceeds of $2,000,000. Each unit consisted of one common share of Neovasc stock and one-half of one common share purchase warrant of Neovasc stock. Each whole warrant entitles the holder to purchase one common share of Neovasc stock at the exercise price of $0.30 per share for a period of one year after the closing date of the offering. Share issue costs were $20,314.

    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Balance Sheets

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                                      June 30,   December 31,
                                                         2009           2008
    -------------------------------------------------------------------------

    ASSETS

    CURRENT
      Cash and cash equivalents                  $  1,340,471   $  2,498,439
      Accounts receivable                             441,783        470,200
      Inventory                                       526,150        341,564
      Prepaid expenses and other assets                58,520         52,356
    -------------------------------------------------------------------------
                                                    2,366,924      3,362,559
    RESTRICTED CASH AND CASH EQUIVALENTS               50,000         50,000
    RETIREMENT ASSETS                                   8,320          8,320
    PROPERTY AND EQUIPMENT                          1,344,730      1,399,644
    -------------------------------------------------------------------------
                                                 $  3,769,974   $  4,820,523
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES

    CURRENT
      Accounts payable and accrued liabilities   $  1,159,173   $  1,218,405
      Current portion of long-term debt                39,650         20,635
    -------------------------------------------------------------------------
                                                    1,198,823      1,239,040
    LONG-TERM DEBT                                    377,279        418,612
    RETIREMENT LIABILITIES                              8,964          8,964
    -------------------------------------------------------------------------
                                                    1,585,066      1,666,616
    -------------------------------------------------------------------------

    SHAREHOLDERS' EQUITY

    Share capital                                  60,588,307     58,607,066
    Contributed surplus                             4,563,255      4,436,804
    Deficit                                       (62,966,654)   (59,889,963)
    -------------------------------------------------------------------------
                                                    2,184,908      3,153,907
    -------------------------------------------------------------------------
                                                 $  3,769,974   $  4,820,523
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Statements of Operations, Comprehensive Loss and Deficit
    For the three and six months ended June 30
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                      Three months ended June 30   Six months ended June 30
                              2009          2008          2009          2008
    -------------------------------------------------------------------------
    SALES
      Product sales   $    529,769  $    433,061  $    828,399  $    837,924
      Consulting
       services             70,555             -       127,409        28,622
    -------------------------------------------------------------------------
                           600,324       433,061       955,808       866,546
    COST OF SALES,
     including
     underutilized
     capacity of $16,038
     (2008: $25,144)       277,265       220,344       427,025       428,604
    -------------------------------------------------------------------------
    GROSS PROFIT           323,059       212,717       528,783       437,942
    -------------------------------------------------------------------------
    EXPENSES
      Selling              163,683       785,491       466,568     1,534,995
      General and
       administration      659,004       779,363     1,409,833     1,317,648
      Product
       development and
       clinical trials     864,702       414,958     1,741,482     1,036,703
      Inventory write
       down                      -        94,404             -        94,404
      Amortization          31,103        75,670        63,459       121,436
    -------------------------------------------------------------------------
                         1,718,492     2,149,886     3,681,342     4,105,186
    -------------------------------------------------------------------------
    LOSS BEFORE OTHER
     INCOME (EXPENSES)  (1,395,433)   (1,937,169)   (3,152,559)   (3,667,244)
    -------------------------------------------------------------------------
    OTHER INCOME (EXPENSES)
      Interest income        1,355        14,208        10,976        23,303
      Interest on
       long-term debt       (2,276)       (5,021)       (5,529)      (12,535)
      Accreted interest
       on repayable
       contribution
       agreement                 -        (3,846)            -        (7,685)
      Gain (Loss) on
       foreign exchange     65,903        16,155        70,421         6,913
    -------------------------------------------------------------------------
                            64,982        21,496        75,868         9,996
    -------------------------------------------------------------------------
    NET LOSS AND
     COMPREHENSIVE LOSS
     FOR THE PERIOD     (1,330,451)   (1,915,673)   (3,076,691)   (3,657,248)
    DEFICIT, BEGINNING
     OF PERIOD         (61,636,203)  (27,371,973)  (59,889,963)  (25,630,398)
    -------------------------------------------------------------------------
    DEFICIT, END
     OF PERIOD        $(62,966,654) $(29,287,646) $(62,966,654) $(29,287,646)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    -------------------------------------------------------------------------
    BASIC AND DILUTED
     LOSS PER SHARE   $      (0.05) $      (0.34) $      (0.14) $      (0.66)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    WEIGHTED AVERAGE
     NUMBER OF
     COMMON SHARES
     OUTSTANDING        27,384,365     5,560,477    22,570,658     5,560,477
    WEIGHTED AVERAGE
     NUMBER OF FULLY
     DILUTED SHARES
     OUTSTANDING        28,215,935     5,560,477    23,406,692     5,560,477
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Statements of Cash Flows
    For the three and six months ended June 30
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                      Three months ended June 30   Six months ended June 30
                              2009          2008          2009          2008
    -------------------------------------------------------------------------
    OPERATING ACTIVITIES
      Net loss for
       the period     $ (1,330,451) $ (1,915,673) $ (3,076,691) $ (3,657,248)
      Items not
       affecting cash
        Inventory write
         down                    -        94,404             -        94,404
        Amortization        31,103        75,670        63,459       121,436
        Interest on
         repayable
         contribution
         agreement               -         3,846             -         7,685
        Stock-based
         compensation       40,399        16,457       126,451        29,740
    -------------------------------------------------------------------------
                        (1,258,949)   (1,725,296)   (2,886,781)   (3,403,983)
      Change in non-cash
       operating assets
       and liabilities
        Accounts
         receivable       (106,089)       38,235        28,417       228,316
        Inventory          (35,974)       81,126      (184,586)      (88,034)
        Prepaid expenses
         and other assets      115       (40,440)       (6,164)     (169,585)
        Accounts payable
         and accrued
         liabilities      (192,967)      118,393       (59,232)      105,493
    -------------------------------------------------------------------------
                        (1,593,864)   (1,527,982)   (3,108,346)   (3,327,793)
    -------------------------------------------------------------------------
    INVESTING ACTIVITY
      Purchase of
       property and
       equipment              (574)       (6,510)       (8,545)      (13,692)
    -------------------------------------------------------------------------
                              (574)       (6,510)       (8,545)      (13,692)
    -------------------------------------------------------------------------
    FINANCING ACTIVITIES
      Repayment of
       long-term debt      (17,287)       (7,265)      (22,318)      (12,035)
      Repayment of
       repayable
       contribution
       agreement                 -        (2,655)            -        (4,383)
      Proceeds from share
       issue, net of
       costs             1,979,686             -     1,979,686             -
      Proceeds from
       exercise of
       stock options             -             -         1,555             -
    -------------------------------------------------------------------------
                         1,962,399        (9,920)    1,958,923       (16,418)
    -------------------------------------------------------------------------
    (DECREASE)/INCREASE
     IN CASH               367,961    (1,544,412)   (1,157,968)   (3,357,903)
    CASH AND CASH
     EQUIVALENTS,
      BEGINNING OF
       PERIOD              972,510     1,428,913     2,498,439     3,242,404
    -------------------------------------------------------------------------
      END OF PERIOD   $  1,340,471  $   (115,499) $  1,340,471  $   (115,499)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    REPRESENTED BY:
      Cash                 538,006      (234,346)      538,006      (234,346)
      Cashable
       guaranteed
       investment
       certificates        802,465       118,847       802,465       118,847
    -------------------------------------------------------------------------
                      $  1,340,471  $   (115,499) $  1,340,471  $   (115,499)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    SUPPLEMENTAL CASH
     FLOW INFORMATION
      Interest paid   $      2,276  $      5,021  $      5,529  $     12,535
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

About Neovasc Inc.

Neovasc Inc. is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer(TM), a novel product in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and as key components in a variety of third-party medical products. For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.


'/>"/>
SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: